UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,383	03/29/2007	Michael Glen Orchard	AC-50-US	9092
	7590 04/06/201 OCIATES LLC	0	EXAMINER	
	EET, SUITE 301		MABRY, JOHN	
MILLBURN, NJ 07041			ART UNIT	PAPER NUMBER
			1625	
			MAIL DATE	DELIVERY MODE
			04/06/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/560,383	ORCHARD ET AL.			
Office Action Summary	Examiner	Art Unit			
	JOHN MABRY	1625			
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the d	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be till will apply and will expire SIX (6) MONTHS from the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) ■ Responsive to communication(s) filed on <u>01 F</u> 2a) ■ This action is FINAL . 2b) ■ This 3) ■ Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1.3.4 and 20-35 is/are pending in the 4a) Of the above claim(s) 4 and 21-35 is/are w 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1.3 and 20 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or and/o	ithdrawn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se cion is required if the drawing(s) is ob	e 37 CFR 1.85(a). vjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/13/05; 9/27/07.	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

Application/Control Number: 10/560,383 Page 2

Art Unit: 1625

DETAILED ACTION

Examiner's Response

Applicant's response on February 1, 2010 filed in response to the Election/Restriction dated December 30, 2009 has been received and duly noted. The Examiner acknowledges Applicants' election of Group I with traverse. The Applicant argues that reference and examples that Examiner provided of EP 0,536,402, in which the restriction requirement was the basis, does not fall within Applicant's claimed invention.

However, Examiner would like to bring compounds as disclosed in WO 02/055498 (PTO-1449) which are certainly relevant prior art. See compound on page 7, line 21 and claims 1-21 on pages 28-30 and thus the instant invention is not a contribution over the prior art. The alkoxy substituent on the phenyl group of R teaches that OR1=C1-C6 alkoxy group (see claim 1 of WO '498).

The claimed invention are not so linked as to form a single general inventive concept and there is a lack of unity of invention because they lack a common core structure and the technical features present fail to define a contribution over the prior art. Accordingly, unity of invention is considered to be lacking and restriction of the invention in accordance with the rules of unity of invention is considered to be proper.

Therefore, since the claims do not relate to a single general inventive concept under PCT Rule 13.1 and lack the same or corresponding special technical features, the claims lack unity of invention and should be limited to only one invention. Restriction is made FINAL.

The method of treatment and process of making claims are not considered in this Office Action.

In view of this response, the status of the rejections/objections of record is as follows:

Status of the Claims

Claims 1, 3 and 20 are pending and rejected.

Claims 2 and 5-19 have been cancelled.

Claims 4 and 21-35 directed towards non-elected subject matter.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 3 and 20 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for "salts", does not reasonably provide enablement for "prodrugs". The specification does not enable any person skilled in the

Application/Control Number: 10/560,383 Page 4

Art Unit: 1625

art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The nature of the invention in the instant case has claims which embrace 1-benzilpiperidine compounds. The scope of "prodrug" is not adequately enabled.

Applicants provide no guidance as how the compounds are made more active *in vivo*.

The choice of a "prodrug" will vary from drug to drug. Therefore, more than minimal routine experimentation would be required to determine which prodrugs will be suitable for the instant invention.

The instant compounds of claims 1, 3 and formula (III) wherein the prodrugs are not described in the disclosure in such a way the one of ordinary skill in the art would no how to prepare the various compounds suggested by said claims. In view of the lack of direction provided in the specification regarding starting materials, the lack of working examples, and the general unpredictability of chemical reactions, it would take an undue amount of experimentation for one skilled in the art to make the claimed compounds and therefore practice the invention.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/560,383

Art Unit: 1625

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.

Page 5

- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 3 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 02/055498 (PTO-1449).

The instant application claims compounds of Formula I where P=a protecting group (benzyl or acetyl) or hydroxyl groups are not protected and R=methylphenyl substituted by OR1 wherein R1=C4-C5 alkyl.

Scope & Content of Prior Art MPEP 2141.01

WO '498 discloses compounds of Formula III where P=a protecting group (benzyl or acetyl) and R=methylphenyl (see compound on page 7) as shown below.

Differences between Prior Art & the Claims MPEP 2141.02

WO '498 differs with the instant application at the alkoxy group on the phenyl ring: WO '498's phenyl group being unsubstituted versus Applicant's C5 alkyl. WO '498 teaches that the phenyl group can be substituted by a C1-C6 alkoxy group at the 4-position (see claim 1 of WO '498).

WO '498 differs with the instant application at the hydroxyl groups on the piperidinyl ring: WO '498's O-P groups versus Applicant's O-H group. However, WO '498 teaches the absence of the protecting groups resulting in just O-H group attached to the piperidinyl ring (see Formula I on page 3 through line 40 of page 4).

Prima Facie Obviousness, Rational & Motivation MPEP 2142-2413

An artisan of ordinary skill would be motivated to achieve the compounds of claimed Formula III using the disclosed species and teachings of WO '498.

The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. The Supreme Court in KSR noted that the analysis supporting a rejection under 35 U.S.C. 103 should be made explicit. The Court quoting In re Kahn, 441 F.3d 977, 988, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006), stated that "[R]ejections on obviousness cannot be sustained by mere conclusory statements; instead, there must be some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness." KSR, 550 U.S. at____, 82 USPQ2d at 1396. Exemplary rationales that may support a conclusion of

Application/Control Number: 10/560,383

Page 7

Art Unit: 1625

obviousness include:

 (A) Combining prior art elements according to known methods to yield predictable results;

- (B) Simple substitution of one known element for another to obtain predictable results;
- (C) Use of known technique to improve similar devices (methods, or products)in the same way;
- (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;
- (E) "Obvious to try" choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success;
- (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;
- (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. See MPEP § 2143 for a discussion of the rationales listed above along with examples illustrating how the cited rationales may be used to support a finding of obviousness. See also MPEP § 2144- §2144.09 for additional guidance regarding support for obviousness determinations.

Art Unit: 1625

The aforementioned reasons above describe rationales that support a conclusion of obviousness based upon the KSR International Co. v. Teleflex Inc. decision. Letters (A) - (E) rationale is supported above.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to

be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 3 and 20 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1-10 and 13 of copending Application No. 10/522,207. Although the conflicting claims are not identical, they are not patentably distinct from each other because of the following.

US case 10/522,207 claims compounds claims 1, 3 of Formula III where P=a protecting group or hydroxyl groups are not protected and R=methylphenyl substituted by OR3 wherein R3=C1-C6 alkyl.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/560,383 Page 10

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Mabry, PhD whose telephone number is (571) 270-1967. The examiner can normally be reached on M-F from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's primary examiner can be reached at (571) 272-0684, first, or the Examiner's supervisor, Janet Andres, PhD, can be reached at (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/John Mabry/ Examiner Art Unit 1625

/Rita J. Desai/

Primary Examiner, Art Unit 1625